Trial · NCT01318083
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 12.5 mg QD and Glimepiride QD or BID | -0.60 | Standard Deviation 0.563 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 25 mg QD and Glimepiride QD or BID | -0.66 | Standard Deviation 0.564 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Glimepiride 1, 2, 3 or 4 mg QD or BID | 0.34 | Standard Deviation 0.611 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 2). | Alogliptin 12.5 mg QD and Glimepiride QD or BID | -0.12 | Standard Deviation 0.244 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 2). | Alogliptin 25 mg QD and Glimepiride QD or BID | -0.13 | Standard Deviation 0.206 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 2). | Glimepiride 1, 2, 3 or 4 mg QD or BID | 0.08 | Standard Deviation 0.229 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 4). | Alogliptin 12.5 mg QD and Glimepiride QD or BID | -0.32 | Standard Deviation 0.357 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 4). | Alogliptin 25 mg QD and Glimepiride QD or BID | -0.36 | Standard Deviation 0.339 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 4). | Glimepiride 1, 2, 3 or 4 mg QD or BID | 0.09 | Standard Deviation 0.351 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 8). | Alogliptin 12.5 mg QD and Glimepiride QD or BID | -0.52 | Standard Deviation 0.488 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 8). | Alogliptin 25 mg QD and Glimepiride QD or BID | -0.59 | Standard Deviation 0.504 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 8). | Glimepiride 1, 2, 3 or 4 mg QD or BID | 0.18 | Standard Deviation 0.525 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Fasting Plasma Glucose (Week 2). | Alogliptin 12.5 mg QD and Glimepiride QD or BID | -17.5 | Standard Deviation 26.05 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (Week 2). | Alogliptin 25 mg QD and Glimepiride QD or BID | -17.4 | Standard Deviation 29.19 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (Week 2). | Glimepiride 1, 2, 3 or 4 mg QD or BID | 0.2 | Standard Deviation 24.12 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (Week 4). | Alogliptin 12.5 mg QD and Glimepiride QD or BID | -21.2 | Standard Deviation 27.33 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (Week 4). | Alogliptin 25 mg QD and Glimepiride QD or BID | -22.9 | Standard Deviation 29.33 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (Week 4). | Glimepiride 1, 2, 3 or 4 mg QD or BID | 2.0 | Standard Deviation 24.83 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (Week 8). | Alogliptin 12.5 mg QD and Glimepiride QD or BID | -22.3 | Standard Deviation 26.40 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (Week 8). | Alogliptin 25 mg QD and Glimepiride QD or BID | -17.4 | Standard Deviation 28.88 | mg/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01318083/results